2.38
+6.73%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nautilus Biotechnology
From its filings with the US Securities and Exchange Commission
Nautilus Biotechnology is based in Seattle, Washington. Its shares trade on Nasdaq under the ticker NAUT. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported a net loss of $59.0m. At that date it held total assets of $191.1m and shareholders' equity of $157.0m.
On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). The Business Combination Agreement provided for, among other things, (i) the domestication of ARYA as a corporation incorporated under the laws of the State of Delaware, upon which ARYA changed its name to “Nautilus Biotechnology, Inc.” (together with its consolidated subsidiary, the “Company” “New Nautilus” or “Nautilus”) and (ii) the merger of Mako Merger Sub with and into Legacy Nautilus (the “Merger”), with Legacy Nautilus as the surviving company in the Merger and, after giving effect to such Merger, Legacy Nautilus becoming a wholly-owned subsidiary of New Nautilus.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 7 Aug 2020
- Employees
- 130
- Website
- nautilus.bio ↗
- Head office
- 2701 EASTLAKE AVE EAST, SEATTLE, WA, 98102
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Matthew PosardIndependent Chairman of the Board$193,782
- Mr. Sujal PatelPresident, Chief Executive Officer, Secretary, Director, since 2021$2.0m
- Ms. Anna MowryChief Financial Officer, Treasurer$781,519
- Ms. Gwen WeldChief People Officer$1.9m
- Mr. Nick NelsonChief Business Officer, Senior Vice President - Business Development
- Dr. Subramanian SankarSenior Vice President - Product Development
- Mr. Kentaro SuzukiChief Marketing Officer$1.0m
- Dr. Parag MallickChief Scientist, Director, since 2021$1.0m
- Mr. Matthew MurphyGeneral Counsel$2.8m
- Ms. Karen AkinsanyaIndependent Director$134,782
- Mr. Michael AltmanIndependent Director$136,782
- Ms. Melissa EpperlyIndependent Director$149,782
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 50
- Social
- 34
- Governance
- 49
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nautilus Biotechnology's Proteome Analysis System offers high-resolution optical imaging for proteome analysis.
- The company's Reagent Kits include sample preparation and multi-affinity probe reagents for multi-cycle analysis.
- Nautilus employs 160 full-time employees focused on proteomics innovation in Seattle.
Weaknesses
- The company's IPO was on 7 August 2020, indicating a relatively new market presence.
- Nautilus Biotechnology has only 130 employees, which may limit scalability.
- The firm's focus on proteomics may restrict diversification in the Health Care sector.
Opportunities
- Expanding proteomics applications in the US Health Care sector could drive growth.
- The Life Sciences Tools & Services industry shows potential for increased adoption.
- Nautilus Biotechnology can leverage its Seattle location for biotech talent acquisition.
Threats
- Competition in the proteomics market may intensify with new entrants.
- The Health Care sector faces regulatory challenges affecting proteomics tools.
- Rapid technological changes could render current proteomics platforms obsolete.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.